miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review.

Autor:	Di Martino MT; Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy., Arbitrio M; Institute for Research and Biomedical Innovation (IRIB), Italian National Council (CNR), Catanzaro, Italy., Caracciolo D; Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy., Cordua A; Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy., Cuomo O; Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy., Grillone K; Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy., Riillo C; Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy., Caridà G; Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy., Scionti F; Institute for Research and Biomedical Innovation (IRIB), Italian National Council (CNR), Messina, Italy., Labanca C; Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy., Romeo C; Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy., Siciliano MA; Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy., D'Apolito M; Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy., Napoli C; Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy., Montesano M; Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy., Farenza V; Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy., Uppolo V; Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy., Tafuni M; Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy., Falcone F; Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy., D'Aquino G; Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy., Calandruccio ND; Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy., Luciano F; Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy., Pensabene L; Department of Surgical and Medical Sciences, Magna Græcia University, Catanzaro, Italy., Tagliaferri P; Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy., Tassone P; Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy.
Jazyk:	angličtina
Zdroj:	Molecular therapy. Nucleic acids [Mol Ther Nucleic Acids] 2022 Feb 11; Vol. 27, pp. 1191-1224. Date of Electronic Publication: 2022 Feb 11 (Print Publication: 2022).
DOI:	10.1016/j.omtn.2022.02.005
Abstrakt:	Among deregulated microRNAs (miRs) in human malignancies, miR-221 has been widely investigated for its oncogenic role and as a promising biomarker. Moreover, recent evidence suggests miR-221 as a fine-tuner of chronic liver injury and inflammation-related events. Available information also supports the potential of miR-221 silencing as promising therapeutic intervention. In this systematic review, we selected papers from the principal databases (PubMed, MedLine, Medscape, ASCO, ESMO) between January 2012 and December 2020, using the keywords "miR-221" and the specific keywords related to the most important hematologic and solid malignancies, and some non-malignant diseases, to define and characterize deregulated miR-221 as a valuable therapeutic target in the modern vision of molecular medicine. We found a major role of miR-221 in this view. Competing Interests: The authors declare no competing interests. (© 2022 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu